Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Ann Hematol

Retrieve available abstracts of 171 articles:
HTML format



Single Articles


    November 2021
  1. ARCANI R, Colle J, Cauchois R, Koubi M, et al
    Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
    Ann Hematol. 2021;100:2799-2803.
    PubMed     Abstract available


  2. REINERT J, Beitzen-Heineke A, Wethmar K, Stelljes M, et al
    Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.
    Ann Hematol. 2021;100:2727-2732.
    PubMed     Abstract available


    October 2021
  3. STANGANELLI C, Torres DC, Ortega C, Marquez ME, et al
    Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients.
    Ann Hematol. 2021 Oct 28. pii: 10.1007/s00277-021-04703.
    PubMed     Abstract available


  4. MENDES FR, da Silva WF, da Costa Bandeira de Melo R, Silveira DRA, et al
    Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting.
    Ann Hematol. 2021 Oct 21. pii: 10.1007/s00277-021-04687.
    PubMed     Abstract available


  5. ZHANG Y, Qian JJ, Shen YJ, Hang SJ, et al
    The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 18. pii: 10.1007/s00277-021-04699.
    PubMed    


  6. HOU HA, Tzeng HE, Liu HY, Chou WC, et al
    Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015.
    Ann Hematol. 2021 Oct 13. pii: 10.1007/s00277-021-04670.
    PubMed     Abstract available


  7. PASVOLSKY O, Shimony S, Ram R, Shimoni A, et al
    Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Ann Hematol. 2021 Oct 9. pii: 10.1007/s00277-021-04693.
    PubMed     Abstract available


  8. UMINSKI K, Khalife R, Fulcher J, Duffett L, et al
    Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 6. pii: 10.1007/s00277-021-04688.
    PubMed    


  9. CHOI HS, Hong J, Hwang SM, Lee JH, et al
    Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Ann Hematol. 2021;100:2567-2574.
    PubMed     Abstract available


  10. SHAH N, Rakszawski K, Nickolich M, Ehmann C, et al
    Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
    Ann Hematol. 2021;100:2585-2592.
    PubMed     Abstract available


  11. BALLO O, Eladly F, Koschade S, Buttner S, et al
    Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy.
    Ann Hematol. 2021;100:2603-2611.
    PubMed     Abstract available


  12. DAS N, Gupta R, Gupta SK, Bakhshi S, et al
    Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
    Ann Hematol. 2021;100:2487-2500.
    PubMed     Abstract available


    September 2021
  13. KIM TH, Choi YW, Ahn MS, Choi YS, et al
    Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia.
    Ann Hematol. 2021 Sep 30. pii: 10.1007/s00277-021-04673.
    PubMed     Abstract available


  14. ZHAO P, Ni M, Ma D, Fang Q, et al
    Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Sep 27. pii: 10.1007/s00277-021-04674.
    PubMed     Abstract available


  15. FAGUNDES EM, Neto NN, Caldas LM, Aragao JR, et al
    Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil.
    Ann Hematol. 2021 Sep 17. pii: 10.1007/s00277-021-04659.
    PubMed    


  16. XU RZ, Karsan A, Xu Z, Berry BR, et al
    A rare de novo pure erythroid leukemia with JAK2 R683S mutation.
    Ann Hematol. 2021 Sep 4. pii: 10.1007/s00277-021-04657.
    PubMed    


  17. YANADA M, Konuma T, Yamasaki S, Mizuno S, et al
    The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04661.
    PubMed     Abstract available


  18. FUJI S, Kida S, Nakata K, Morishima T, et al
    Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer Registry.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04631.
    PubMed     Abstract available


  19. HEINICKE T, Krahl R, Kahl C, Cross M, et al
    Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
    Ann Hematol. 2021;100:2387-2398.
    PubMed     Abstract available


  20. QI J, Zhang R, Cai C, Wang H, et al
    HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant.
    Ann Hematol. 2021;100:2351-2361.
    PubMed     Abstract available


  21. CHEN X, Liu C, Zhang A, Wu W, et al
    Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
    Ann Hematol. 2021;100:2269-2277.
    PubMed     Abstract available


    August 2021
  22. GUERY R, Suarez F, Lanternier F, Bougnoux ME, et al
    Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa.
    Ann Hematol. 2021 Aug 13. pii: 10.1007/s00277-021-04622.
    PubMed     Abstract available


  23. TACHIBANA T, Kanda J, Ishizaki T, Najima Y, et al
    Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
    Ann Hematol. 2021 Aug 6. pii: 10.1007/s00277-021-04607.
    PubMed     Abstract available


  24. MIAN AA, Haberbosch I, Khamaisie H, Agbarya A, et al
    Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K).
    Ann Hematol. 2021;100:2023-2029.
    PubMed     Abstract available


  25. WELLBROCK J, Behrmann L, Muschhammer J, Modemann F, et al
    The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia.
    Ann Hematol. 2021 Aug 1. pii: 10.1007/s00277-021-04602.
    PubMed     Abstract available


    July 2021
  26. MI R, Chen L, Yang H, Zhang Y, et al
    Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia.
    Ann Hematol. 2021 Jul 27. pii: 10.1007/s00277-021-04621.
    PubMed     Abstract available


  27. MATSUDA K, Jo T, Toyama K, Nakazaki K, et al
    Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan.
    Ann Hematol. 2021 Jul 26. pii: 10.1007/s00277-021-04620.
    PubMed     Abstract available


  28. ALRAWASHDH N, Sweasy J, Erstad B, McBride A, et al
    Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04600.
    PubMed     Abstract available


  29. ELNAIR R, Ellithi M, Kallam A, Shostrom V, et al
    Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04603.
    PubMed     Abstract available


  30. KONG J, Qin YZ, Zhao XS, Hou Y, et al
    Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04606.
    PubMed     Abstract available


  31. MICHAELIS S, Pichler A, Stelzer I, Schoffmann L, et al
    Aggressive NK-cell leukemia with hemophagocytosis in a Caucasian patient.
    Ann Hematol. 2021 Jul 16. pii: 10.1007/s00277-021-04585.
    PubMed    


  32. HARA R, Onizuka M, Kikkawa E, Shiraiwa S, et al
    Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2021 Jul 11. pii: 10.1007/s00277-021-04587.
    PubMed     Abstract available


  33. BARZEGAR M, Farsani MA, Rafiee M, Amiri V, et al
    Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARalpha transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04579.
    PubMed     Abstract available


  34. TANIGAWA T, Sakurai M, Kato J, Mizuno K, et al
    Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04586.
    PubMed    


  35. GREIL R, Tedeschi A, Moreno C, Anz B, et al
    Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Ann Hematol. 2021;100:1733-1742.
    PubMed     Abstract available


  36. GADGEEL M, AlQanber B, Buck S, Taub JW, et al
    Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.
    Ann Hematol. 2021;100:1695-1700.
    PubMed     Abstract available


    June 2021
  37. VIRK H, Rana S, Sharma P, Bose PL, et al
    Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
    Ann Hematol. 2021 Jun 22. pii: 10.1007/s00277-021-04574.
    PubMed     Abstract available


  38. WYSOCKA-SLOWIK A, Gil L, Slebioda Z, Kregielczak A, et al
    Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation.
    Ann Hematol. 2021 Jun 12. pii: 10.1007/s00277-021-04568.
    PubMed     Abstract available


  39. KRECAK I, Cengic M, Skoric I, Nakic M, et al
    Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Ann Hematol. 2021 Jun 10. pii: 10.1007/s00277-021-04570.
    PubMed    


  40. DOU X, Zheng F, Zhang L, Jin J, et al
    Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study.
    Ann Hematol. 2021 Jun 5. pii: 10.1007/s00277-021-04544.
    PubMed     Abstract available


  41. AL-SARAYFI D, Meeuwes FO, Munnink TO, Plattel W, et al
    Successful treatment of hairy cell leukemia variant with obinutuzumab.
    Ann Hematol. 2021 Jun 4. pii: 10.1007/s00277-021-04559.
    PubMed    


  42. LARIBI K, Sobh M, Ghez D, Baugier de Materre A, et al
    Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.
    Ann Hematol. 2021;100:1359-1376.
    PubMed     Abstract available


  43. ZENG Z, Ly C, Daver N, Cortes J, et al
    High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
    Ann Hematol. 2021;100:1485-1496.
    PubMed     Abstract available


    May 2021
  44. HEUSER M, Smith BD, Fiedler W, Sekeres MA, et al
    Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Ann Hematol. 2021 May 12. pii: 10.1007/s00277-021-04545.
    PubMed    


  45. KONG J, Chen N, Li M, Zhang J, et al
    Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2021 May 6. pii: 10.1007/s00277-021-04530.
    PubMed    


  46. DEVOS T, Havelange V, Theunissen K, Meers S, et al
    Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Ann Hematol. 2021 May 4. pii: 10.1007/s00277-021-04507.
    PubMed     Abstract available


  47. GONZALEZ JS, Perusini MA, Basquiera AL, Alfonso G, et al
    Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.
    Ann Hematol. 2021 May 1. pii: 10.1007/s00277-021-04539.
    PubMed     Abstract available


  48. SALAMONOWICZ-BODZIOCH M, Fraczkiewicz J, Czyzewski K, Zajac-Spychala O, et al
    Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation.
    Ann Hematol. 2021;100:1283-1293.
    PubMed     Abstract available


  49. TANG KHK, Ip AHW, Kwong YL
    Clonal derivation of sequential seminoma and acute megakaryoblastic leukaemia.
    Ann Hematol. 2021;100:1337-1339.
    PubMed    


  50. HORIUCHI M, Yoshida M, Yamasaki K, Sakagami R, et al
    Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
    Ann Hematol. 2021;100:1329-1331.
    PubMed    


  51. BERNARDI S, Zanaglio C, Farina M, Polverelli N, et al
    dsDNA from extracellular vesicles (EVs) in adult AML.
    Ann Hematol. 2021;100:1355-1356.
    PubMed    


    April 2021
  52. MARTINEZ SANCHEZ MP, Megias-Vericat JE, Rodriguez-Veiga R, Vives S, et al
    A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Ann Hematol. 2021 Apr 29. pii: 10.1007/s00277-021-04542.
    PubMed     Abstract available


  53. ZHAO H, Sun J, Yan L, Jin B, et al
    Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.
    Ann Hematol. 2021 Apr 24. pii: 10.1007/s00277-021-04533.
    PubMed     Abstract available


  54. KE P, Zhang X, Liu S, Zhu Q, et al
    The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
    Ann Hematol. 2021 Apr 22. pii: 10.1007/s00277-021-04528.
    PubMed     Abstract available


  55. ONAKA T, Kato-Ogura A, Otsuka Y, Iwai F, et al
    A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
    Ann Hematol. 2021 Apr 12. pii: 10.1007/s00277-021-04516.
    PubMed    


  56. OWATTANAPANICH W, Herzig J, Jahn N, Panina E, et al
    Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Ann Hematol. 2021 Apr 10. pii: 10.1007/s00277-021-04513.
    PubMed     Abstract available


  57. QIAN Y, Chen Y, Li X
    CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Ann Hematol. 2021 Apr 6. pii: 10.1007/s00277-021-04491.
    PubMed     Abstract available


  58. MODI D, Singh V, Kim S, Ayash L, et al
    Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
    Ann Hematol. 2021;100:969-978.
    PubMed     Abstract available


  59. HU L, Charwudzi A, Li Q, Zhu W, et al
    Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.
    Ann Hematol. 2021;100:1003-1012.
    PubMed     Abstract available


  60. SCHULER E, Wagner-Drouet EM, Ajib S, Bug G, et al
    Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Ann Hematol. 2021;100:959-968.
    PubMed     Abstract available


  61. RETTIG AR, Ihorst G, Bertz H, Lubbert M, et al
    Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis.
    Ann Hematol. 2021 Apr 1. pii: 10.1007/s00277-021-04494.
    PubMed     Abstract available


    March 2021
  62. LEOTTA S, Markovic U, Pirosa MC, Stella S, et al
    The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
    Ann Hematol. 2021 Mar 28. pii: 10.1007/s00277-021-04504.
    PubMed     Abstract available


  63. HEUSER M, Smith BD, Fiedler W, Sekeres MA, et al
    Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Ann Hematol. 2021 Mar 19. pii: 10.1007/s00277-021-04465.
    PubMed     Abstract available


  64. SHOUMARIYEH K, Jung J, Rassner M, Dold SM, et al
    Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
    Ann Hematol. 2021 Mar 13. pii: 10.1007/s00277-021-04490.
    PubMed    


  65. LIU J, Zhang XH, Xu LP, Wang Y, et al
    Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Mar 13. pii: 10.1007/s00277-021-04488.
    PubMed     Abstract available


  66. BALLO O, Eladly F, Buttner S, Stratmann JA, et al
    Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy.
    Ann Hematol. 2021 Mar 11. pii: 10.1007/s00277-021-04482.
    PubMed     Abstract available


  67. SCALZULLI E, Caocci G, Efficace F, Rizzo L, et al
    Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
    Ann Hematol. 2021 Mar 7. pii: 10.1007/s00277-021-04477.
    PubMed     Abstract available


  68. LI T, Chen H, Zhang Y, Zeng Y, et al
    Very rare lineage switch from acute myeloid leukemia with BCR-ABL1 to B-lymphoblastic leukemia.
    Ann Hematol. 2021 Mar 5. pii: 10.1007/s00277-021-04483.
    PubMed    


  69. ZUCENKA A, Maneikis K, Pugaciute B, Ringeleviciute U, et al
    Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
    Ann Hematol. 2021 Mar 4. pii: 10.1007/s00277-021-04471.
    PubMed     Abstract available


  70. BRUNE MM, Stussi G, Lundberg P, Vela V, et al
    Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
    Ann Hematol. 2021 Mar 2. pii: 10.1007/s00277-021-04467.
    PubMed     Abstract available


  71. STEINER N, Brunelli L, Hetzenauer G, Lindner B, et al
    Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience.
    Ann Hematol. 2021;100:809-816.
    PubMed     Abstract available


  72. YU WJ, Sun YQ, Han TT, Ye PP, et al
    Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study.
    Ann Hematol. 2021;100:799-808.
    PubMed     Abstract available


  73. BOSCH F, Navarro B, Crespo M, Alcoceba M, et al
    Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
    Ann Hematol. 2021;100:825-830.
    PubMed     Abstract available


  74. LAHLIMI FZ, Tazi I
    A rare cause of respiratory failure in acute myeloid leukaemia patient.
    Ann Hematol. 2021;100:831-832.
    PubMed    


    February 2021
  75. ISOBE M, Konuma T, Masuko M, Uchida N, et al
    Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.
    Ann Hematol. 2021 Feb 23. pii: 10.1007/s00277-021-04464.
    PubMed     Abstract available


  76. OLIVA S, De Paoli L, Ruggeri M, Caltagirone S, et al
    A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
    Ann Hematol. 2021;100:437-443.
    PubMed     Abstract available


  77. WANG Z, Liu W, Wang M, Li Y, et al
    Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
    Ann Hematol. 2021;100:465-479.
    PubMed     Abstract available


  78. GHOSH S, Chakraborty M, Samanta S, Sinha N, et al
    Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.
    Ann Hematol. 2021;100:395-403.
    PubMed     Abstract available


  79. ENGEL NW, Reinert J, Borchert NM, Panagiota V, et al
    Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow.
    Ann Hematol. 2021;100:499-503.
    PubMed     Abstract available


  80. AKIMOTO M, Sakurai A, Nishiyama-Fujita Y, Ito C, et al
    The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
    Ann Hematol. 2021 Feb 1. pii: 10.1007/s00277-021-04440.
    PubMed     Abstract available


    January 2021
  81. BOUCLET F, Calleja A, Dilhuydy MS, Veronese L, et al
    Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
    Ann Hematol. 2021 Jan 25. pii: 10.1007/s00277-021-04419.
    PubMed     Abstract available


  82. DUAN W, Liu X, Zhao X, Jia J, et al
    Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
    Ann Hematol. 2021 Jan 20. pii: 10.1007/s00277-021-04432.
    PubMed     Abstract available


  83. TONG J, Zhang L, Liu H, Xu X, et al
    Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival.
    Ann Hematol. 2021 Jan 20. pii: 10.1007/s00277-021-04413.
    PubMed     Abstract available


  84. VOIGT M, Sinn K, Malouhi A, Gecks T, et al
    HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient.
    Ann Hematol. 2021 Jan 14. pii: 10.1007/s00277-021-04409.
    PubMed    


  85. AMIT O, On YB, Perez G, Shargian-Alon L, et al
    Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.
    Ann Hematol. 2021 Jan 13. pii: 10.1007/s00277-021-04398.
    PubMed     Abstract available


  86. LIAO PW, Wang RC, Chen TC, Teng CJ, et al
    Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
    Ann Hematol. 2021 Jan 13. pii: 10.1007/s00277-020-04372.
    PubMed    


  87. SCHLAWECK S, Brossart P, Heine A
    Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah's Witness patient.
    Ann Hematol. 2021 Jan 12. pii: 10.1007/s00277-021-04403.
    PubMed    


  88. KERUAKOUS AR, Balakrishna P, Schmidt SA, Autry MT, et al
    Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant.
    Ann Hematol. 2021 Jan 12. pii: 10.1007/s00277-021-04408.
    PubMed    


  89. MARTIN-MORO F, Garcia-Cosio M, Marquet-Palomanes J, Lopez-Gutierrez M, et al
    Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
    Ann Hematol. 2021 Jan 9. pii: 10.1007/s00277-021-04393.
    PubMed    


  90. BRECCIA M, Celant S, Olimpieri PP, Olimpieri OM, et al
    Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
    Ann Hematol. 2021 Jan 7. pii: 10.1007/s00277-021-04406.
    PubMed     Abstract available


  91. MA YR, Xu LP, Zhang XH, Liu KY, et al
    Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings.
    Ann Hematol. 2021 Jan 7. pii: 10.1007/s00277-020-04359.
    PubMed     Abstract available


  92. CAOCCI G, Mulas O, Capodanno I, Bonifacio M, et al
    Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
    Ann Hematol. 2021 Jan 3. pii: 10.1007/s00277-020-04392.
    PubMed     Abstract available


  93. CHEN Q, Zhu XL, Zhao X, Liu X, et al
    Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Ann Hematol. 2021 Jan 2. pii: 10.1007/s00277-020-04380.
    PubMed     Abstract available


  94. LIU J, Shen L, Huang H, Gao X, et al
    A rare case of donor-derived promyelocytic sarcoma in a kidney transplant recipient.
    Ann Hematol. 2021;100:295-296.
    PubMed    


    December 2020
  95. ANGENENDT L, Hilgefort I, Mikesch JH, Schluter B, et al
    Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Ann Hematol. 2020 Dec 19. pii: 10.1007/s00277-020-04382.
    PubMed     Abstract available


  96. YAMASAKI S, Mori J, Kanda J, Imahashi N, et al
    Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT.
    Ann Hematol. 2020;99:2927-2937.
    PubMed     Abstract available


  97. CHEN H, Qin Y, Yang J, Liu P, et al
    Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.
    Ann Hematol. 2020;99:2847-2857.
    PubMed     Abstract available


    November 2020
  98. FUJI S, Kida S, Nakata K, Morishima T, et al
    Correction to: Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Regist
    Ann Hematol. 2020 Nov 28. pii: 10.1007/s00277-020-04352.
    PubMed     Abstract available


  99. LU Y, Zhao YL, Zhang JP, Xiong M, et al
    Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a s
    Ann Hematol. 2020 Nov 24. pii: 10.1007/s00277-020-04355.
    PubMed     Abstract available


  100. RASEKH EO, Osman R, Ibraheem D, Madney Y, et al
    Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.
    Ann Hematol. 2020 Nov 23. pii: 10.1007/s00277-020-04354.
    PubMed     Abstract available


  101. WANG YH, Lin CC, Hsu CL, Hung SY, et al
    Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125.
    Ann Hematol. 2020 Nov 23. pii: 10.1007/s00277-020-04358.
    PubMed     Abstract available


  102. ROBAK E, Jesionek-Kupnicka D, Robak T
    Skin changes in hairy cell leukemia.
    Ann Hematol. 2020 Nov 20. pii: 10.1007/s00277-020-04349.
    PubMed     Abstract available


  103. ZAPPASODI P, Brociner M, Merati G, Nizzoli ME, et al
    Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Ann Hematol. 2020 Nov 11. pii: 10.1007/s00277-020-04333.
    PubMed    


  104. MORI Y, Sasaki K, Ito Y, Kuriyama T, et al
    Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study.
    Ann Hematol. 2020 Nov 5. pii: 10.1007/s00277-020-04310.
    PubMed     Abstract available


    October 2020
  105. YUAN XL, Tan YM, Shi JM, Zhao YM, et al
    Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2020 Oct 31. pii: 10.1007/s00277-020-04326.
    PubMed     Abstract available


  106. FUJI S, Kida S, Nakata K, Morishima T, et al
    Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Ann Hematol. 2020 Oct 21. pii: 10.1007/s00277-020-04308.
    PubMed     Abstract available


  107. CORNELISSEN LL, Kreuger AL, Caram-Deelder C, Middelburg RA, et al
    Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia - a nested case-control study.
    Ann Hematol. 2020 Oct 17. pii: 10.1007/s00277-020-04298.
    PubMed     Abstract available


  108. PHUKAN A, Mandal PK, Dolai TK
    Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India.
    Ann Hematol. 2020 Oct 6. pii: 10.1007/s00277-020-04289.
    PubMed     Abstract available


  109. TAVARES M, Chacim S, Mariz JM
    Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Ann Hematol. 2020 Oct 1. pii: 10.1007/s00277-020-04291.
    PubMed    


  110. MOORE DC, Nelson V, Muslimani A
    Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.
    Ann Hematol. 2020 Oct 1. pii: 10.1007/s00277-020-04285.
    PubMed    


  111. LU Y, Zhao YL, Zhang JP, Xiong M, et al
    Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Ann Hematol. 2020 Oct 1. pii: 10.1007/s00277-020-04283.
    PubMed     Abstract available


  112. JENTZSCH M, Bill M, Grimm J, Brauer D, et al
    Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
    Ann Hematol. 2020;99:2417-2427.
    PubMed     Abstract available


  113. VIARDOT A, Locatelli F, Stieglmaier J, Zaman F, et al
    Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Ann Hematol. 2020;99:2215-2229.
    PubMed     Abstract available


  114. KAWADA K, Ohta T, Fukuda H, Hayashi T, et al
    Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
    Ann Hematol. 2020;99:2429-2436.
    PubMed     Abstract available


  115. BENETATOS L, Benetatou A, Vartholomatos G
    Long non-coding RNAs and MYC association in hematological malignancies.
    Ann Hematol. 2020;99:2231-2242.
    PubMed     Abstract available


  116. ZHANG L, Wang M, Wang Z, Zeng Z, et al
    Identification of a novel ETV6 truncated fusion gene in myeloproliferative neoplasm, unclassifiable with t(4;12)(q12;p13).
    Ann Hematol. 2020;99:2445-2447.
    PubMed    


  117. TEY A, Mohan B, Cheah R, Dendle C, et al
    Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.
    Ann Hematol. 2020;99:2455-2456.
    PubMed    


    September 2020
  118. RAMOS-PENAFIEL C, Olarte-Carrillo I, Maldonado RC, de la Cruz Rosas A, et al
    Association of three factors (ABCB1 gene expression, steroid response, early response at day + 8) on the response to induction in patients with acute lymphoblastic leukemia.
    Ann Hematol. 2020 Sep 27. pii: 10.1007/s00277-020-04277.
    PubMed     Abstract available


  119. JING Y, Li YF, Wan H, Liu DH, et al
    Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.
    Ann Hematol. 2020 Sep 26. pii: 10.1007/s00277-020-04251.
    PubMed     Abstract available


  120. BALLO O, Kreisel EM, Eladly F, Brunnberg U, et al
    Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy.
    Ann Hematol. 2020 Sep 24. pii: 10.1007/s00277-020-04274.
    PubMed     Abstract available


  121. WEI H, Kuang P, Liu T
    Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis.
    Ann Hematol. 2020 Sep 22. pii: 10.1007/s00277-020-04258.
    PubMed     Abstract available


  122. ZHAO Y, Rehder C, Wang E
    Circulating blastoid cells: acute leukemia, prolymphocytic leukemia, or something else?
    Ann Hematol. 2020 Sep 15. pii: 10.1007/s00277-020-04270.
    PubMed    


  123. SHI X, Jiang Q, You H, Liu Y, et al
    Rare synchronous co-existence of acute myeloid leukemia and hairy cell leukemia in a same patient.
    Ann Hematol. 2020 Sep 14. pii: 10.1007/s00277-020-04272.
    PubMed    


  124. SHARGIAN-ALON L, Wolach O, Rozovski U, Yahav D, et al
    Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
    Ann Hematol. 2020 Sep 6. pii: 10.1007/s00277-020-04232.
    PubMed     Abstract available


  125. YU J, Ge X, Luo Y, Shi J, et al
    Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia.
    Ann Hematol. 2020 Sep 5. pii: 10.1007/s00277-020-04199.
    PubMed     Abstract available


  126. MINAMIGUCHI H, Fujita H, Atsuta Y, Asou N, et al
    Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia.
    Ann Hematol. 2020 Sep 2. pii: 10.1007/s00277-020-04245.
    PubMed     Abstract available


  127. DUONG VH, Begna KH, Kashanian S, Sweet K, et al
    Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study.
    Ann Hematol. 2020;99:2119-2124.
    PubMed     Abstract available


  128. KOLB HJ, Schmid C
    The FLAMSA concept-past and future.
    Ann Hematol. 2020;99:1979-1988.
    PubMed     Abstract available


  129. VALE CA, Egan PC, Ingham R, Farmakiotis D, et al
    Antibiotic use during cytarabine consolidation in acute myeloid leukemia.
    Ann Hematol. 2020 Sep 1. pii: 10.1007/s00277-020-04238.
    PubMed     Abstract available


    August 2020
  130. ICHIKAWA S, Fujiwara T, Saito K, Fukuhara N, et al
    A novel case of gammadelta T cell leukemia with recurrent genetic abnormalities accompanied by agranulocytosis.
    Ann Hematol. 2020 Aug 31. pii: 10.1007/s00277-020-04241.
    PubMed    


  131. LIU W, Burger JA, Xu J, Tang Z, et al
    LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
    Ann Hematol. 2020 Aug 24. pii: 10.1007/s00277-020-04223.
    PubMed     Abstract available


  132. WULLENKORD R, Reicherts C, Mikesch JH, Marx J, et al
    Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
    Ann Hematol. 2020 Aug 22. pii: 10.1007/s00277-020-04227.
    PubMed    


  133. PEPE S, Scalzulli E, Colafigli G, Di Prima A, et al
    Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Ann Hematol. 2020 Aug 19. pii: 10.1007/s00277-020-04217.
    PubMed     Abstract available


  134. TACHIBANA T, Najima Y, Akahoshi Y, Hirabayashi S, et al
    The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2020 Aug 15. pii: 10.1007/s00277-020-04212.
    PubMed     Abstract available


  135. LE BOURGEOIS A, Labopin M, Marcais A, de Latour RP, et al
    Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFG
    Ann Hematol. 2020;99:1855-1862.
    PubMed     Abstract available


  136. KARA ALI R, Surme S, Balkan II, Salihoglu A, et al
    An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality.
    Ann Hematol. 2020;99:1925-1932.
    PubMed     Abstract available


  137. FLORES V, Miranda R, Merino L, Gonzalez C, et al
    SARS-CoV-2 infection in children with febrile neutropenia.
    Ann Hematol. 2020;99:1941-1942.
    PubMed    


    July 2020
  138. BETTELLI F, Giusti D, Morselli M, Colaci E, et al
    Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study.
    Ann Hematol. 2020 Jul 23. pii: 10.1007/s00277-020-04191.
    PubMed    


  139. SHAHSWAR R, Beutel G, Gabdoulline R, Koenecke C, et al
    Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
    Ann Hematol. 2020 Jul 23. pii: 10.1007/s00277-020-04181.
    PubMed    


  140. MEGIAS-VERICAT JE, Solana-Altabella A, Ballesta-Lopez O, Martinez-Cuadron D, et al
    Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
    Ann Hematol. 2020 Jul 18. pii: 10.1007/s00277-020-04186.
    PubMed     Abstract available


  141. IKEDA Y, Yamanouchi J, Takenaka K
    Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
    Ann Hematol. 2020 Jul 16. pii: 10.1007/s00277-020-04185.
    PubMed    


  142. CHENG FM, Tien JZ, Chen TT, Yeh SP, et al
    Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
    Ann Hematol. 2020 Jul 3. pii: 10.1007/s00277-020-04168.
    PubMed    


  143. ZANELLI M, Ricci S, Zizzo M, Sanguedolce F, et al
    Bone marrow coexistence of chronic lymphocytic leukemia and Langerhans cell sarcoma.
    Ann Hematol. 2020 Jul 3. pii: 10.1007/s00277-020-04167.
    PubMed    


  144. KUNADT D, Dransfeld C, Dill C, Schmiedgen M, et al
    Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia.
    Ann Hematol. 2020 Jul 3. pii: 10.1007/s00277-020-04163.
    PubMed     Abstract available


  145. CHENG Z, Luo Y, Zhang Y, Wang Y, et al
    A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction.
    Ann Hematol. 2020;99:1561-1564.
    PubMed     Abstract available


  146. KOVAL SV, Gluzman DF, Sklyarenko LM, Ivanivska TS, et al
    Hematological malignancies in Ukraine in post-Chernobyl era: sources of data and their preliminary analysis.
    Ann Hematol. 2020;99:1543-1550.
    PubMed     Abstract available


    June 2020
  147. HINZE A, Rinke J, Hochhaus A, Ernst T, et al
    Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.
    Ann Hematol. 2020 Jun 23. pii: 10.1007/s00277-020-04152.
    PubMed    


  148. LI Z, Lai Y, Zhang X, Xu L, et al
    Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2020 Jun 23. pii: 10.1007/s00277-020-04155.
    PubMed     Abstract available


  149. MARTINS F, Kruszewski M, Scarpelli I, Schoumans J, et al
    Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia.
    Ann Hematol. 2020 Jun 16. pii: 10.1007/s00277-020-04114.
    PubMed     Abstract available


  150. HOCHMAN MJ, Martin DB
    Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
    Ann Hematol. 2020 Jun 16. pii: 10.1007/s00277-020-04091.
    PubMed    


  151. ROBAK P, Jesionek-Kupnicka D, Kupnicki P, Polliack A, et al
    Multifocal osteolytic lesions in hairy cell leukemia-the importance of PET/CT in diagnosis and assessment.
    Ann Hematol. 2020 Jun 12. pii: 10.1007/s00277-020-04121.
    PubMed    


  152. STEMLER J, Koehler P, Maurer C, Muller C, et al
    Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.
    Ann Hematol. 2020 Jun 8. pii: 10.1007/s00277-020-04107.
    PubMed     Abstract available


  153. YANAGISAWA H, Mizuta S, Kawabata H, Fujimoto S, et al
    Faggot cells in acute myeloid leukemia with t(7;11)(p15;p15) and NUP98-HOXA9 fusion.
    Ann Hematol. 2020 Jun 8. pii: 10.1007/s00277-020-04122.
    PubMed    


  154. BECKER H, Pfeifer D, Ihorst G, Pantic M, et al
    Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Ann Hematol. 2020 Jun 6. pii: 10.1007/s00277-020-04082.
    PubMed     Abstract available


  155. ARCHIBALD WJ, Rabe KG, Kabat BF, Herrmann J, et al
    Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Ann Hematol. 2020 Jun 1. pii: 10.1007/s00277-020-04094.
    PubMed     Abstract available


    May 2020
  156. MULAS O, Caocci G, Stagno F, Bonifacio M, et al
    Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
    Ann Hematol. 2020 May 30. pii: 10.1007/s00277-020-04102.
    PubMed     Abstract available


  157. SCALZULLI E, Colafigli G, Latagliata R, Pepe S, et al
    Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.
    Ann Hematol. 2020 May 28. pii: 10.1007/s00277-020-04096.
    PubMed     Abstract available


  158. CHEN Q, Zhao X, Fu HX, Chen YH, et al
    Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia.
    Ann Hematol. 2020 May 26. pii: 10.1007/s00277-020-04080.
    PubMed     Abstract available


  159. MAAKARON JE, Ozga MP, Mannis GN, Pulley W, et al
    Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.
    Ann Hematol. 2020 May 6. pii: 10.1007/s00277-020-04054.
    PubMed    


  160. YANADA M, Takami A, Yamasaki S, Arai Y, et al
    Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century.
    Ann Hematol. 2020 May 4. pii: 10.1007/s00277-020-04051.
    PubMed     Abstract available


    April 2020
  161. HELBIG G, Koclega A, Wieczorkiewicz-Kabut A, Wozniczka K, et al
    Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.
    Ann Hematol. 2020 Apr 24. pii: 10.1007/s00277-020-04026.
    PubMed     Abstract available


  162. HORISAWA Y, Kondo T, Hishizawa M, Yamashita K, et al
    A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
    Ann Hematol. 2020 Apr 21. pii: 10.1007/s00277-020-04029.
    PubMed    


  163. BRUMMENDORF TH, Gambacorti-Passerini C, Bushmakin AG, Cappelleri JC, et al
    Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
    Ann Hematol. 2020 Apr 19. pii: 10.1007/s00277-020-04018.
    PubMed     Abstract available


  164. GAO M, Zhao X
    Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
    Ann Hematol. 2020 Apr 19. pii: 10.1007/s00277-020-04037.
    PubMed    


  165. GUPTA C, Kaulfuss S, Gorlich K, Othman B, et al
    Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.
    Ann Hematol. 2020 Apr 15. pii: 10.1007/s00277-020-04001.
    PubMed    


  166. MIN GJ, Cho BS, Park SS, Park S, et al
    Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
    Ann Hematol. 2020 Apr 8. pii: 10.1007/s00277-020-04010.
    PubMed     Abstract available


  167. SPIESS B, Kleiner H, Flach J, Fabarius A, et al
    Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients.
    Ann Hematol. 2020 Apr 6. pii: 10.1007/s00277-020-04007.
    PubMed     Abstract available


  168. APEL A, Ofran Y, Wolach O, Shimony S, et al
    Safety and efficacy of blinatumomab: a real world data.
    Ann Hematol. 2020;99:835-838.
    PubMed     Abstract available


  169. BUSSAGLIA E, Pratcorona M, Carricondo M, Sansegundo L, et al
    Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies).
    Ann Hematol. 2020;99:765-772.
    PubMed     Abstract available


    March 2020
  170. OZBAGCIVAN O, Akarsu S, Nazli EC, Lebe B, et al
    Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ann Hematol. 2020 Mar 27. pii: 10.1007/s00277-020-04009.
    PubMed    


    February 2020
  171. GRUHN B, Brodt G, Wittig S, Ernst T, et al
    Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL.
    Ann Hematol. 2020 Feb 18. pii: 10.1007/s00277-020-03957.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: